Study design
thrombo-embolism, infections, hepatic and renal dysfunctions, cardio-pulmonary disorders, coagulation abnormalities, MP, THA
RHEUMATOID ARTHRITIS, TRANEXAMIC ACID ALLERGY, INFECTIONS, HEMATOLOGICAL DISORDERS, MALIGNANCIES
Our study adhered strictly to the protocols established by the Institutional Ethics Review Board of our institution and complied meticulously with the Guidelines on Standards for Reporting of Trials (CONSORT). We enrolled all patients undergoing initial Total Hip Arthroplasty (THA) in this study. However, we established exclusion criteria that included: methylprednisolone or tranexamic acid allergy, rheumatoid arthritis, existing infections, Body Mass Index (BMI) exceeding 30 kg/m2, one-stage bilateral hip replacement, revision surgery, coagulation abnormalities, hematological disorders, malignancies, severe cardio-pulmonary disorders, critical hepatic and renal dysfunctions, history of thrombo-embolism, preoperative hemoglobin less than 90 g/L, and usage of anticoagulation drugs within a week prior to surgery. The participants were randomly allocated to either the Tranexamic Acid (TXA) group or the Methylprednisolone plus Tranexamic Acid (MP + TXA) group as part of a single, single-blind, randomized controlled trial. Patient assignment was randomly ordered based on parity prior to surgery. We obtained written informed consent from each participant.